Efficacy of modified minimally invasive surgical technique in the treatment of human intrabony defects with or without use of rhPDGF-BB gel: a randomized controlled trial.
To evaluate the efficacy of modified minimally invasive surgical technique (M-MIST) technique with local delivery of recombinant human platelet derived growth factor (rhPDGF-BB) gel in the treatment of intrabony defects. Twenty-four healthy subjects were included in the present double-blinded, randomized, controlled study. Test group was treated with M-MIST and rhPDGF-BB and control group with M-MIST alone. The mean probing depth (PD), clinical attachment level (CAL) and gingival recession, cementoenamel junction to base of the defect (CEJ-BD), defect depth (DD) and cementoenamel junction to alveolar crest (CEJ-AC), at baseline to 6 months post-operatively in both the groups were statistically significant. Inter-group comparison for gain in attachment level (CAL-G), probing depth reduction (PD-R) and change in gingival margin position linear bone growth (LBG), percentage bone fill, residual defect depth (residual DD) and the change in alveolar crest position revealed no statistically significant differences. Gain in CAL and LBG was 3 ± 0.89 mm and 1.89 ± 0.6 in test group and 2.64 ± 0.67 mm and 1.85 ± 1.18 mm in control group, respectively, and did not show statistical significance. The improvement in both groups could be attributed to the novel surgical technique rather than addition of rhPDGF-BB.